Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord
-
Melina Ramallo [3] ; Irene Carreras-Sánchez [4] ; Alba López-Fernández [4] ; Roberto Vélez [1] ; Màrius Aguirre [2] ; Sara Feldman [1] ; Joaquim Vives [5]
-
[1] Universitat Autònoma de Barcelona
Universitat Autònoma de Barcelona
Barcelona, España
-
[2] Hospital Vall d'Hebron
Hospital Vall d'Hebron
Barcelona, España
-
[3] School of Medicine, National Rosario University, Argentina
-
[4] Banc de Sang i Teixits
-
[5] Researh Council of the Rosario National University, Argentina
-
- Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 36, Nº. 1, 2021, págs. 19-30
- Idioma: inglés
- Enlaces
-
Resumen
Compliance with current regulations for the development of innovative medicines require the testing of candidate therapies in relevant translational animal models prior to human use. This poses a great challenge when the drug is composed of cells, not only because of the living nature of the active ingredient but also due to its human origin, which can subsequently lead to a xenogeneic response in the animals. Although immunosuppression is a plausible solution, this is not suitable for large animals and may also influence the results of the study by altering mechanisms of action that are, in fact, poorly understood. For this reason, a number of procedures have been developed to isolate homologous species-specific cell types to address preclinical pharmacodynamics, pharmacokinetics and toxicology. In this work, we present and discuss advances in the methodologies for derivation of multipotent Mesenchymal Stromal Cells derived from the umbilical cord, in general, and Wharton’s jelly, in particular, from medium to large animals of interest in orthopaedics research, as well as current and potential applications in studies addressing proof of concept and preclinical regulatory aspects.
